Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Pediatrics Reports
Published in: Current Pediatrics Reports 2/2013

01-06-2013 | Endocrinology (LL Levitsky, Section Editor)

Growth Hormone and Treatment Controversy; Long-Term Safety of rGH

Authors: Sara A. DiVall, Sally Radovick

Published in: Current Pediatrics Reports | Issue 2/2013

Login to get access

Abstract

The availability of recombinant human growth hormone (rGH) for the treatment of growth disorders has provided an unlimited supply for replacement in patients with growth hormone insufficiency, but also for short stature due to Turner syndrome, renal failure, Prader-Willi syndrome, small for gestational age and idiopathic short stature. Considering the potential for side effects in the use of a growth promoting agent, the community of physicians and pharmaceutical manufacturers developed systematic methods to survey for short- and long-term effects. Recently published data from the National Cooperative Growth Study, managed by Genentech, concluded that GH has a ‘favorable profile’. In 2012, results from the European Union’s Safety and Appropriateness of GH treatment in Europe (EU SAGhE) study about the long-term mortality in GH-treated patients were published in two separate manuscripts. This review will examine the issue of safety of rGH in order to better inform practitioners as they consider initiation of therapy with patients.
Literature
1.
•• Carel JC, Ecosse E, Landier F, et al. Long-term mortality after recombinant growth hormone treatment for isolated growth hormone deficiency or childhood short stature: preliminary report of the French SAGhE study. J Clin Endocrinol Metab. 2012;97:416–25. This manuscript reports results from the European Union’s Safety and Appropriateness of GH treatment in Europe (EU SAGhE) study in France about the long-term mortality in GH-treated patients. This study found that persons treated with rGH were at an increased risk of death.
2.
•• Savendahl L, Maes M, Albertsson-Wikland K, et al. Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study. J Clin Endocrinol Metab. 2012;97:E213–7. This manuscript reports results from the European Union’s Safety and Appropriateness of GH treatment in Europe (EU SAGhE) study in Belgium, Sweden, and the Netherlands about the long-term mortality in GH-treated patients.
3.
Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly—2011 update. Endocr Pract. 2011;17(Suppl 4):1–44.PubMedCrossRef
4.
Mestron A, Webb S, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004;151:439–46.PubMedCrossRef
5.
Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89–95.PubMedCrossRef
6.
Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.PubMedCrossRef
7.
•• Bell J, Parker KL, Swinford RD, et al. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95:167–77. This manuscript reports data collected from the National Cooperative Growth Study (NCGS), a large registry of patients treated with rGH managed by Genentech. In general they reported that short-term risks are relatively rare and the authors deemed GH to have a ‘favorable profile’.
8.
Allen DB. Growth hormone post-marketing surveillance: safety, sales, and the unfinished task ahead. J Clin Endocrinol Metab. 2010;95:52–5.PubMedCrossRef
9.
Watanabe S, Mizuno S, Oshima LH, et al. Leukemia and other malignancies among GH users. J Pediatr Endocrinol. 1993;6:99–108.PubMedCrossRef
10.
Allen DB, Rundle AC, Graves DA, Blethen SL. Risk of leukemia in children treated with human growth hormone: review and reanalysis. J Pediatr. 1997;131:S32–6.PubMedCrossRef
11.
Nishi Y, Tanaka T, Takano K, et al. Recent status in the occurrence of leukemia in growth hormone-treated patients in Japan. GH Treatment Study Committee of the Foundation for Growth Science, Japan. J Clin Endocrinol Metab. 1999;84:1961–5.PubMedCrossRef
12.
Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91:3494–8.PubMedCrossRef
13.
Swerdlow AJ, Reddingius RE, Higgins CD, et al. Growth hormone treatment of children with brain tumors and risk of tumor recurrence. J Clin Endocrinol Metab. 2000;85:4444–9.PubMedCrossRef
14.
Moshang T Jr, Rundle AC, Graves DA, et al. Brain tumor recurrence in children treated with growth hormone: the National Cooperative Growth Study experience. J Pediatr. 1996;128:S4–7.PubMedCrossRef
15.
Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 2002;360:273–7.PubMedCrossRef
16.
Mills JL, Schonberger LB, Wysowski DK, et al. Long-term mortality in the United States cohort of pituitary-derived growth hormone recipients. J Pediatr. 2004;144:430–6.PubMedCrossRef
17.
Child CJ, Zimmermann AG, Woodmansee WW, et al. Assessment of primary cancers in GH-treated adult hypopituitary patients: an analysis from the Hypopituitary Control and Complications Study. Eur J Endocrinol. 2011;165:217–23.PubMedCrossRef
18.
Sperling MA. Long-term therapy with growth hormone: bringing sagacity to SAGHE. J Clin Endocrinol Metab. 2012;97:81–3.PubMedCrossRef
19.
Rosenfeld RG, Cohen P, Robison LL, et al. Long-term surveillance of growth hormone therapy. J Clin Endocrinol Metab. 2012;97:68–72.PubMedCrossRef
20.
Malozowski S. Reports of increased mortality and GH: will this affect current clinical practice? J Clin Endocrinol Metab. 2012;97:380–3.PubMedCrossRef
21.
Ayuk J, Clayton RN, Holder G, et al. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-i concentrations, predict excess mortality in patients with acromegaly. J Clin Endocrinol Metab. 2004;89:1613–7.PubMedCrossRef
22.
Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31:301–42.PubMedCrossRef
23.
Carel JC, Ecosse E, Nicolino M, et al. Adult height after long term treatment with recombinant growth hormone for idiopathic isolated growth hormone deficiency: observational follow up study of the French population based registry. BMJ. 2002;325:70.
Metadata
Title
Growth Hormone and Treatment Controversy; Long-Term Safety of rGH
Authors
Sara A. DiVall
Sally Radovick
Publication date
01-06-2013
Publisher
Current Science Inc.
Published in
Current Pediatrics Reports / Issue 2/2013
Electronic ISSN: 2167-4841
DOI
https://doi.org/10.1007/s40124-013-0009-5

Other articles of this Issue 2/2013

Current Pediatrics Reports 2/2013 Go to the issue

Cardiology (WW Lai, Section Editor)

Beyond Hypoplastic Left Heart Syndrome: The Spectrum of Congenital Heart Disease Associated with Left Ventricular Hypoplasia

Cardiology (WW Lai, Section Editor)

Pulmonary Arterial Hypertension Associated with Congenital Heart Disease

Cardiology (WW Lai, Section Editor)

The Fontan Circulation: The Known, the Unknown and the Plausible

Cardiology (WW Lai, Section Editor)

Transcatheter Pulmonary Valve Replacement: A Current Review

Endocrinology (LL Levitsky, Section Editor)

Endocrine Aspects of Childhood Obesity

Endocrinology (LL Levitsky, Section Editor)

Update on Treatment of Type 1 Diabetes in Childhood